NanoLogix Seeks Development & Marketing Partner for Their Sub 1-Hour COVID-19 Detection Tests
June 03, 2020 at 10:25 pm IST
NanoLogix, Inc. is seeking a partner or partners for obtaining FDA Emergency Use Authorization, if required, and for development and marketing of their sub 1-hour COVID-19 Point of Care modified-ELISA detection test. This Rapid Viral Assay can also be configured for other viruses, such as, but not limited to, HIV, HPV, Hepatitis, MERS, and SARS-1. A Home-Test version of the COVID-19 test has the potential of 30-minute results using a nasopharyngeal swab or saliva samples.